Status:
UNKNOWN
Respiratory Microbiome and COPD Exacerbations (RESMECOPD)
Lead Sponsor:
Corporacion Parc Tauli
Collaborating Sponsors:
Hospital de Sant Pau
Hospital Clinic of Barcelona
Conditions:
Pulmonary Disease, Chronic Obstructive
Exacerbation COPD
Eligibility:
All Genders
40-75 years
Brief Summary
The global objective of this coordinated project is to test the following hypotheses: 1) the lung microbiome in chronic obstructive pulmonary disease (COPD) is different in patients suffering from fre...
Eligibility Criteria
Inclusion
- Spirometry: FEV1/FVC \< 70%; FEV1 between 50 and 80% predicted (GOLD II/III)
- Clinical Stability (no therapeutic change and/or use of antibiotics) during 8 weeks. - The treatment received will be registered for post-hoc studies stratified by this condition.
Exclusion
- Drug addiction, alcohol abuse,
- Use of long-term oral or nebulised antibiotic therapy.
- History of allergies, asthma or other chronic respiratory disease, sanitary worker, working exposure to dust or fumes.
- Other diseases: Severe cardiovascular, neurological, psychiatric, renal, hepatic or gastrointestinal , that might interfere with the daily life activities.
Key Trial Info
Start Date :
March 7 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03432234
Start Date
March 7 2016
End Date
December 1 2020
Last Update
January 23 2020
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Corporació Sanitaria Parc Tauli
Sabadell, Barcelona, Spain, 08208
2
Hospital Germans Trias i Pujol
Badalona, Spain
3
Hospital Clínic
Barcelona, Spain
4
Hospital de Bellitge
Barcelona, Spain